tetano
Editor, Senior Moderator
J Hum Hypertens
. 2020 Nov 9.
doi: 10.1038/s41371-020-00436-w. Online ahead of print.
The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment
Cenk Sarı[SUP] 1 [/SUP], Ersin ?ağrı Şimşek[SUP] 2 [/SUP], ?ner ?zdoğan[SUP] 3 [/SUP]
Affiliations
Abstract
Concern has arisen about the role played in coronavirus disease 2019 (COVID-19) infection by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). This study was designed to assess the practice behaviors of physicians toward hypertension treatment with ACE-i or ARBs during the COVID-19 pandemic. A self-administered survey questionnaire consisting of 26 questions about current hypertension treatment with ACE-i/ ARBs was applied to cardiologists, internists, and family physicians in central and western Turkey, between 01 and 19 May 2020. A total of 460 physicians were approached, and 220 (47.8%) participated in the study. Of the total respondents, 78.7% reported that they had not changed their antihypertensive medication prescribing pattern, 8.6% of clinicians had changed ACE-i/ ARBs medicine of patients during the COVID-19 pandemic and 12.7% of them were undecided. The median (?interquartile range) score indicating general reliance level of physicians in ACE-i/ARBs therapy was 8 ? 4 (range, 1-10). In multiple comparison analyses, the general reliance level in ACE-i/ARBs, reliance level when starting a new ACEi/ARBs and changing behavior in heart failure patients were significantly different with regard to the specialties (p:0.02, p:0.009, p:0.005 respectively). Although most of the physicians found the publications about ACE-i/ ARBs during the COVID-19 pandemic untrustworthy, there were variable levels of knowledge and reliance among different physicians and specialty groups. In general, the ACE-i/ ARBs prescribing habits were not affected by safety concerns during the COVID-19 pandemic in Turkey.
. 2020 Nov 9.
doi: 10.1038/s41371-020-00436-w. Online ahead of print.
The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment
Cenk Sarı[SUP] 1 [/SUP], Ersin ?ağrı Şimşek[SUP] 2 [/SUP], ?ner ?zdoğan[SUP] 3 [/SUP]
Affiliations
- PMID: 33168943
- DOI: 10.1038/s41371-020-00436-w
Abstract
Concern has arisen about the role played in coronavirus disease 2019 (COVID-19) infection by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). This study was designed to assess the practice behaviors of physicians toward hypertension treatment with ACE-i or ARBs during the COVID-19 pandemic. A self-administered survey questionnaire consisting of 26 questions about current hypertension treatment with ACE-i/ ARBs was applied to cardiologists, internists, and family physicians in central and western Turkey, between 01 and 19 May 2020. A total of 460 physicians were approached, and 220 (47.8%) participated in the study. Of the total respondents, 78.7% reported that they had not changed their antihypertensive medication prescribing pattern, 8.6% of clinicians had changed ACE-i/ ARBs medicine of patients during the COVID-19 pandemic and 12.7% of them were undecided. The median (?interquartile range) score indicating general reliance level of physicians in ACE-i/ARBs therapy was 8 ? 4 (range, 1-10). In multiple comparison analyses, the general reliance level in ACE-i/ARBs, reliance level when starting a new ACEi/ARBs and changing behavior in heart failure patients were significantly different with regard to the specialties (p:0.02, p:0.009, p:0.005 respectively). Although most of the physicians found the publications about ACE-i/ ARBs during the COVID-19 pandemic untrustworthy, there were variable levels of knowledge and reliance among different physicians and specialty groups. In general, the ACE-i/ ARBs prescribing habits were not affected by safety concerns during the COVID-19 pandemic in Turkey.